No Data
No Data
No Data
No Data
No Data
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) fell sharply during Monday's session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic d
BenzingaApr 16 02:11
Marinus Pharmaceuticals, Cartesian Therapeutics, Adial Pharmaceuticals Among Healthcare Movers
Seeking AlphaApr 15 22:00
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&P 500 also
BenzingaApr 15 22:00
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 09, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc.(NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics
GlobeNewswireApr 9 19:00
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 04, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of therapeutics targeting
GlobeNewswireApr 4 19:00
ProMIS Neurosciences Q4 EPS $(0.09) Beats $(0.17) Estimate
ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.17) by 47.06 percent. This is a 90 percent increase over losses of $(0
BenzingaApr 2 20:09
No Data
No Data